Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
- Thursday, June 10, 2021, 7:02
- Finance
- Add a comment
OSLO, Norway, June 10, 2021 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS between 21.9 and 25.0 months from the randomized phase 1/2 trial of ONCOS-102 in…
About the Author
adminasapcorp has written 41672 stories on this site.